The Technical Analyst
Regulus Therapeutics Inc [RGLS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Regulus Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.77% $2.22
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 145.33 mill |
| EPS: | -1.580 |
| P/E: | -1.410 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 65.47 mill |
| Avg Daily Volume: | 3.11 mill |
| RATING 2024-04-24 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.410 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.24x |
| Company: PE -1.410 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.093 (-50.76%) $-1.127 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.945 - 2.54 ( +/- 13.17%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-14 | Papadopoulos Stelios | Buy | 250 000 | Common Stock |
| 2024-01-18 | Calsada Crispina | Sell | 5 468 | Common Stock |
| 2024-01-18 | Aker Christopher Ray | Sell | 5 468 | Common Stock |
| 2024-01-18 | Hagan Joseph P | Sell | 14 580 | Common Stock |
| 2024-01-12 | Klassen Preston | Buy | 120 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 98.54 |
| Last 86 transactions |
| Buy: 13 400 605 | Sell: 39 678 |
Forecast:
16:00 - $2.24
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.24
Forecast 2: 16:00 - $2.24
Forecast 3: 16:00 - $2.24
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.22 (-1.77% ) |
| Volume | 0.0918 mill |
| Avg. Vol. | 3.11 mill |
| % of Avg. Vol | 2.95 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RGLS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RGLS
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2024-03-21 16:05:00 - Press Release
Regulus Therapeutics Reports Fourth Quarter And Year-end 2023 Financial Results And Recent Updates
Positive topline data from the second cohort of patients in phase 1b multiple-ascending dose (mad) clinical trial of rgls8429 for the treatment of autosomal dominant polycystic kidney disease (adpkd) oversubscribed $100 million private placement; expected to extend cash runway into h1 2026 completed enrollment of the third cohort of patients in the mad study; data anticipated mid-2024 completed type d meeting with fda to discuss pathway for accelerated approval of rgls8429 san diego, march 21, 2024 /prnewswire/ -- regulus therapeutics inc. (nasdaq: rgls), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting micrornas (the "company" or "regulus"), today reported financial results for the fourth quarter and year ended december 31, 2023, and provided a corporate update...
2024-03-12 06:32:00 - Press Release
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement Of Equity
San diego , march 12, 2024 /prnewswire/ -- regulus therapeutics inc. (nasdaq: rgls), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting micrornas (the "company" or "regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. the oversubscribed financing includes participation from new and existing institutional investors, including adage capital partners l.p.
2024-03-12 06:30:00 - Press Release
Regulus Therapeutics Announces Positive Topline Data From The Second Cohort Of Patients In Its Phase 1b Multiple-ascending Dose (mad) Clinical Trial Of Rgls8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (adpkd)
Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in pc1 and pc2 cohort 3 fully enrolled with data readout anticipated in mid-2024; cohort 4 screening to start in 2q 2024 company to hold conference call at 8:30am et today san diego , march 12, 2024 /prnewswire/ -- regulus therapeutics inc. (nasdaq: rgls), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting micrornas (the "company" or "regulus"), today announced positive topline results from the second cohort of patients in its phase 1b mad study of rgls8429 for the treatment of adpkd...
2024-01-02 16:05:00 - Press Release
Regulus Therapeutics Announces Completion Of Enrollment In Third Cohort Of Phase 1b Multiple-ascending Dose (mad) Clinical Trial Of Rgls8429 For The Treatment Of Patients With Autosomal Dominant Polycystic Kidney Disease (adpkd)
San diego , jan. 2, 2024 /prnewswire/ -- regulus therapeutics inc. (nasdaq: rgls), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting micrornas (the "company" or "regulus"), today announced it has completed enrollment in the third cohort of patients in the phase 1b mad study of rgls8429 for the treatment of adpkd. "the completion of our third and final randomized placebo-controlled cohort in the phase 1b mad study is an exciting step for regulus, and we are happy to reach this stage of development for rgls8429," said jay hagan, ceo of regulus.
2023-11-22 08:00:00 - Press Release
Regulus Therapeutics To Present At The 6th Annual Evercore Isi Healthconx Conference
San diego , nov. 22, 2023 /prnewswire/ -- regulus therapeutics inc . (nasdaq: rgls), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting micrornas (the "company" or "regulus"), today announced that ceo jay hagan will be participating in a fireside chat at the 6th annual evercore isi healthconx conference on wednesday november 29, at 10:25 a.m.
Latest News
2024-03-13 13:11:11 - Zacks Investment Research
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
2023-11-22 08:00:00 - PRNewsWire
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
SAN DIEGO , Nov. 22, 2023 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November 29, at 10:25 a.m.
2023-08-23 12:06:00 - GuruFocus
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
Long-established in the Biotechnology industry, Regulus Therapeutics Inc ( RGLS , Financial) has enjoyed a stellar reputation. It has recently witnessed a surge of 13.27%, juxtaposed with a three-month change of 4.18%.
2023-04-14 14:25:07 - Zacks Investment Research
Regulus (RGLS) Surges on Enrollment Completion for RGLS8429
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
2022-11-10 21:49:13 - Seeking Alpha
Regulus Therapeutics, Inc. (RGLS) Q3 2022 Earnings Call Transcript
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q3 2022 Earnings Conference Call November 10, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Jay Hagan - President, CEO & Director Denis Drygin - Chief Scientific Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities Operator Hello, and welcome to the Regulus Therapeutics Inc. Q3 2022 Earnings Conference Call. [Operator Instructions].
2022-09-13 13:32:21 - Zacks Investment Research
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Regulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending study of its lead candidate RGLS8429 in autosomal dominant polycystic kidney disease.
2022-09-13 06:00:00 - PennyStocks
Hot Penny Stocks to Know About Right Now? 3 to Watch
Here's what you need to know about trading penny stocks on September 13th The post Hot Penny Stocks to Know About Right Now? 3 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-02 16:05:00 - PRNewsWire
Regulus Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , Sept. 2, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in two upcoming investor conferences.
2022-08-11 18:51:07 - Seeking Alpha
Regulus Therapeutics, Inc. (RGLS) CEO Joseph Hagan on Q2 2022 Results - Earnings Call Transcript
Regulus Therapeutics, Inc. (NASDAQ:RGLS ) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Crispina Calsada - CFO Joseph Hagan - President & CEO Conference Call Participants Yi Chen - H.C. Wainwright & Co. Operator Good morning, and welcome to the Regulus Therapeutics Second Quarter Financial Results Conference Call.
2022-05-27 17:04:07 - PennyStocks
Top Penny Stocks to Buy Now? 3 to Watch in June 2022
